Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors

This study has been terminated.
(Closed by sponsor.)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Dawn L. Hershman, Columbia University
ClinicalTrials.gov Identifier:
NCT00930527
First received: June 29, 2009
Last updated: July 22, 2014
Last verified: February 2013

June 29, 2009
July 22, 2014
June 2009
May 2011   (final data collection date for primary outcome measure)
A change in serum free and total estradiol levels. [ Time Frame: At week 3 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00930527 on ClinicalTrials.gov Archive Site
A change in the frequency of analgesics consumed [ Time Frame: At 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors
Randomized Phase II Study of Omega-3-Fatty Acid on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients

There are no data regarding the use of supplements to alleviate the musculoskeletal pain and stiffness inducted by the use of aromatase inhibitors. This study is designated to test the safety and efficacy of omega 3 fatty acid supplementation to alleviate musculoskeletal pain in postmenopausal breast cancer patients.

There are no data regarding the use of these supplements in other types of musculoskeletal pain and discomfort, namely AI induced joint pain and joint stiffness. Given the lack of effective treatments for AI induced joint pain/ stiffness and the safety and efficacy of omega 3 fatty acid for musculoskeletal pain, it is therefore reasonable to test the efficacy of these dietary supplements in a population of postmenopausal breast cancer patients who experience joint pain related to aromatase inhibitors. Since women with hormone receptor positive breast cancer require long term hormonal therapy, an important objective is minimizing long term side effects to enhance patient compliance and improve quality of life.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Breast Cancer
Dietary Supplement: Omega-3 Fatty Acid
4g per day for 3 weeks
Other Name: Lovaza
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
10
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age >21 years
  • Postmenopausal status defined as cessation of menses for >1 year or FSH >20 mIU/mL or bilateral oophorectomy.
  • History of stage I, II or III hormone receptor-positive breast cancer, without metastatic disease
  • Currently taking a third-generation aromatase inhibitor for at least 3 months
  • Clinical symptoms of knee and/or hand joint pain and/or stiffness for at least 3 months prior to study entry
  • Ongoing musculoskeletal pain/stiffness in hand and/or knee joints (50 or higher on the 100 point global assessment VAS) that started or increased since initiating aromatase inhibitor therapy, and has been present for at least 3 months.
  • Patients must agree to refrain from use of omega-3-fatty acid from sources outside of this study
  • If taking bisphosphonates, on a stable dose for at least 1 month and tolerating the dose. Patients must agree to refrain from initiating bisphosphonate use during the course of the study, therefore it is recommended that routine bone density testing be performed prior to enrollment or after completing trial.
  • ECOG performance status 0-2.
  • Signed informed consent

Exclusion Criteria:

  • Use of omega-3-fatty acid within the past three (3) months
  • Concurrent medical/arthritic disease that could confound or interfere with evaluation of pain or efficacy including: Inflammatory arthritis (e.g., rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatica), gout, episodes of acute monarticular arthritis clinically consistent with pseudogout, Paget's disease affecting the study joint, a history of septic arthritis or avascular necrosis or intra-articular fracture of the study joint, Wilson's disease, hemochromatosis, alkaptonuria, or primary osteochondromatosis.
  • History of significant collateral ligament, anterior cruciate ligament or meniscal injury of the index joint requiring surgery or non-weight bearing (requiring use of crutches or cane) for more than 3 weeks (minor ligamentous injury prior to 6 months is not an exclusion).
  • History of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to study entry.
  • History of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient.
  • Allergy to, or history of significant clinical or laboratory adverse experience associated with omega-3 fatty acid
  • Inability to understand and complete study questionnaires including questions requiring a visual analog scale (VAS) response.
  • Inability to understand the study procedures and/or give written informed consent.
  • Alcohol use in excess of 3 mixed drinks/day.
  • Corticosteroid treatment as follows:

    1. Use of oral corticosteroids within the previous four weeks.
    2. Exposure to intramuscular corticosteroids within one month prior to entering the study.
    3. Administration of intra-articular steroids to the study joint, within 3 months of Randomization Visit.
    4. Administration of intra-articular steroids to any other joint, within 3 months of Randomization Visit.
  • Intra-articular injection of hyaluronic acid or congeners into the study joint within 12 months.
  • Topical analgesics (e.g., capsaicin preparations) to the study joint, or any oral analgesics (e.g., opiates, tramadol; with the exception of ibuprofen and acetaminophen) within 2 weeks of Randomization Visit or during the study.
  • Implementation of any other medical therapy for arthritis within one month prior to entry.
  • Other medications, unrelated to the patient's joint pain/stiffness must have been used at a stable dosage for at least 1 month. In addition, it should be anticipated that the dose of the concomitant medication will be stable during the entire treatment period.
  • Participation in another clinical study with an investigational agent within the last 4 weeks.
  • Exposure to omega-3-fatty acid within 3 months of Baseline Visit.
Female
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00930527
AAAD8300
Yes
Dawn L. Hershman, Columbia University
Columbia University
GlaxoSmithKline
Principal Investigator: Dawn Hershman, MD Columbia University
Columbia University
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP